News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Conference News ACC 2022 PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI Todd Neale April 03, 2022
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Conference News ACC 2018 SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients Michael O'Riordan March 11, 2018
News Conference News ACC 2018 ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit Michael O'Riordan March 10, 2018
News Conference News ACC 2017 Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS Michael O'Riordan March 19, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2013 Will Watchman PREVAIL? Positive Study Pulled from ACC Meeting Yael L. Maxwell March 08, 2013
News Conference News ACC 2012 CPORT-E: PCI Outcomes Similar Regardless of On-Site Cardiac Surgery March 25, 2012